The relationship between maternal plasma leptin levels and fetal growth restriction

Area of Science:

• Reproductive Endocrinology
• Maternal-Fetal Medicine
• Metabolic Regulation

Background:

• Leptin, a satiety hormone from adipose tissue and placenta, is elevated in severe preeclampsia.
• Preeclampsia is linked to small for gestational age (SGA) infants.
• The association between maternal leptin and fetal growth restriction without preeclampsia remains unclear.

Purpose of the Study:

• To investigate the relationship between maternal plasma leptin levels and fetal growth in non-preeclamptic and preeclamptic women.
• To determine if elevated maternal leptin is associated with fetal growth restriction independent of preeclampsia.

Main Methods:

• Cross-sectional study comparing maternal plasma leptin levels in SGA and appropriate for gestational age (AGA) groups.
• Inclusion of both non-preeclamptic (n=98) and preeclamptic (n=40) pregnant women.
• Multiple linear regression analysis to identify factors influencing maternal leptin levels.

Main Results:

• Significantly higher maternal plasma leptin in SGA groups compared to AGA groups in both non-preeclamptic and preeclamptic cohorts (P<0.05).
• Maternal BMI, mean arterial blood pressure, and Delta SD of neonatal body weight were significant predictors of maternal leptin.
• Maternal BMI and Delta SD of neonatal body weight positively correlated with leptin in non-preeclamptic subjects.

Conclusions:

• Maternal plasma leptin levels are elevated in pregnancies complicated by fetal growth restriction (SGA).
• Leptin elevation reflects, at least partly, impaired fetal growth, irrespective of preeclampsia status.
• Maternal factors like BMI and blood pressure influence leptin levels during pregnancy.